Home > Insider Trading > Filing (0001140361-15-037233)

Filing Details

Accession Number:: 0001140361-15-037233
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-10-08 17:50:14
Reporting Period:: 2015-10-06

Filing Date:: 2015-10-08
Accepted Time:: 2015-10-08 17:50:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
872589	Regeneron Pharmaceuticals Inc	REGN	Pharmaceutical Preparations (2834)	133444607

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1121404	Sanofi	54, Rue La Boetie Paris I0 75008		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-10-06	1,965	$470.41	23,099,495	No	4	P	Indirect	See note
Common Stock	Acquisiton	2015-10-06	3,625	$471.64	23,103,120	No	4	P	Indirect	See note
Common Stock	Acquisiton	2015-10-06	2,650	$472.37	23,105,770	No	4	P	Indirect	See note
Common Stock	Acquisiton	2015-10-06	1,000	$473.31	23,106,770	No	4	P	Indirect	See note
Common Stock	Acquisiton	2015-10-06	1,000	$474.27	23,107,770	No	4	P	Indirect	See note
Common Stock	Acquisiton	2015-10-06	700	$476.35	23,108,470	No	4	P	Indirect	See note
Common Stock	Acquisiton	2015-10-06	100	$476.85	23,108,570	No	4	P	Indirect	See note

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See note
No	4	P	Indirect	See note
No	4	P	Indirect	See note
No	4	P	Indirect	See note
No	4	P	Indirect	See note
No	4	P	Indirect	See note
No	4	P	Indirect	See note

Footnotes

The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $470.00 to $470.99 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,309,018 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Purchase prices range from $471.00 to $471.94 per share, inclusive.
Purchase prices range from $472.00 to $472.96 per share, inclusive.
Purchase prices range from $473.00 to $473.76 per share, inclusive.
Purchase prices range from $474.01 to $474.45 per share, inclusive.
Purchase prices range from $475.82 to $476.75 per share, inclusive.
Purchase price was $476.85 per share.